Home Featured Page 139

Featured

Latest

Film Club: Music for Mushrooms

Psychedelic Approvals on Track, Advocacy in Flux: A Washington Dispatch on FDA, Election Year and ‘Ibogaine Exceptionalism’

Betty Aldworth & Ismail Ali: MAPS Co-Executive Directors on Leadership, Research, and the Future of Psychedelics

Gov. Spencer Cox Signs Utah’s H.B. 390 Into Law, Authorizing Psychedelic Research for Veterans With PTSD

Why Did Psychedelics Relieve My Chronic Pain?

Psychedelics Weekly – Oregon Measure 109: Approaching the Proposed Final Rules

MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD

Racing Beyond Racemic: A Look at Ketamine Drug Development Ahead of...

Surprising Results: Psilocybin Trial for Depression Alleviates Chronic Pain

PT373 – Integrative Psychiatry & The Safety of At-Home Ketamine

Interview | Elliot Marseille, Global Initiative for Psychedelic Science Economics...

Psychedelics Weekly – Wonderland Controversy and Colorado Proposition 122

Psychedelic Bulletin #123: Colorado Psilocybin Therapy Prop Passes While Swathes of...

EDITOR PICKS

Film Club: Music for Mushrooms

Psychedelic Approvals on Track, Advocacy in Flux: A Washington Dispatch on...

Betty Aldworth & Ismail Ali: MAPS Co-Executive Directors on Leadership, Research,...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Film Club: Music for Mushrooms

Psychedelic Approvals on Track, Advocacy in Flux: A Washington Dispatch on FDA, Election Year and ‘Ibogaine Exceptionalism’

Betty Aldworth & Ismail Ali: MAPS Co-Executive Directors on Leadership, Research, and the Future of Psychedelics

Gov. Spencer Cox Signs Utah’s H.B. 390 Into Law, Authorizing Psychedelic Research for Veterans With PTSD

ShroomskiCon 2026

Why Did Psychedelics Relieve My Chronic Pain?

Psychedelics Weekly – Oregon Measure 109: Approaching the Proposed Final Rules

MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD

Racing Beyond Racemic: A Look at Ketamine Drug Development Ahead of...

Surprising Results: Psilocybin Trial for Depression Alleviates Chronic Pain

PT373 – Integrative Psychiatry & The Safety of At-Home Ketamine

Interview | Elliot Marseille, Global Initiative for Psychedelic Science Economics...

Psychedelics Weekly – Wonderland Controversy and Colorado Proposition 122

Psychedelics Weekly – Wonderland Controversy and Colorado Proposition 122

Psychedelic Bulletin #123: Colorado Psilocybin Therapy Prop Passes While Swathes of...

EDITOR PICKS

Film Club: Music for Mushrooms

Psychedelic Approvals on Track, Advocacy in Flux: A Washington Dispatch on...

Betty Aldworth & Ismail Ali: MAPS Co-Executive Directors on Leadership, Research,...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY